Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.
Post-remission measurable residual disease directs treatment choice and improves outcomes for patients with intermediate-risk acute myeloid leukemia in CR1.
复制标题
DOI：
10.1007/s12185-022-03441-6
复制
发表时间：
2022-12
影响因子：
2.1
通讯作者：
Yu, Jifeng
中科院分区：
文献类型：
--
作者：
Han, Lijie;Li, Yilu;Wu, Jiaying;Peng, Jie;Han, Xiaolin;Zhao, Hongmian;He, Chen;Li, Yuanyuan;Wang, Weimin;Zhang, Mengmeng;Li, Yafei;Sun, Hui;Cao, Haixia;Sang, Li'na;Jiang, Zhongxing;Yu, Jifeng
关键词：
本研究回顾分析了中危急性髓系白血病(AML)首次完全缓解(CR1)患者的可测量残留病(MRD)与预后的关系。这项研究招募了235名患有中等风险AML的年轻患者。化疗后第1、2、3个周期(分别为MRD_1~3)用多参数流式细胞仪检测MRD。第1周期和第2周期后未发现明显的相关性。但MRD3阳性组的5年复发率(n = 99)高于阴性组(n = 136)(48.7%vs 13.7%，P = 0.005)，而5年无瘤生存率(DFS)和总生存率(OS)低于阴性组(43.2%vs 81.0%和45.4%vs 84.1%；P = 0.003和0.005)。在MRD3阳性组中，异基因造血干细胞移植导致较低的5年复发率、较高的DFS和OS率(分别为22.3%比71.5%、65.9%比23.0%和67.1%比23.9%；P <； 分别为0.001、0.002和0.022)，但不影响MRD阴性组。MRD3可作为缓解后治疗选择的指标，并有助于改善CR1中危AML的预后。网上版载有补充材料，可在10.1007/s12185-022-03441-6查阅。
This study retrospectively investigated in which cycle measurable residual disease (MRD) is associated with prognosis in patients in first complete remission (CR1) of intermediate-risk acute myeloid leukemia (AML). The study enrolled 235 younger patients with intermediate-risk AML. MRD was evaluated by multiparameter flow cytometry after the 1st, 2nd, and 3rd chemotherapy cycles (MRD1–3, respectively). No significant association was detected after the 1st and 2nd cycles. However, the 5-year incidence of relapse was higher in the MRD3-positive group (n = 99) than in the negative group (n = 136) (48.7% vs. 13.7%, P = 0.005), while 5-year disease-free survival (DFS) and overall survival (OS) were lower in the MRD3-positive group than in the negative group (43.2% vs. 81.0% and 45.4% vs. 84.1%; P = 0.003 and 0.005, respectively). Allogeneic hematopoietic stem cell transplantation led to a lower 5-year relapse, and higher DFS and OS rates than chemotherapy in the MRD3-positive group (22.3% vs. 71.5%, 65.9% vs. 23.0%, and 67.1% vs. 23.9%; P < 0.001, 0.002, and 0.022, respectively), but did not affect the MRD-negative group. MRD3 could serve as an indicator for post-remission treatment choice and help improve outcomes for intermediate-risk AML in CR1. The online version contains supplementary material available at 10.1007/s12185-022-03441-6.
登录
查看更多内容
影响因子：
10.1
作者：
Keating, Armand;DaSilva, Gisela;Weisdorf, Daniel J.
通讯作者：
Weisdorf, Daniel J.
影响因子：
6.2
作者：
Gorin, Norbert-Claude;Labopin, Myriam;Mohty, Mohamad
通讯作者：
Mohty, Mohamad
影响因子：
11.4
作者：
Burnett AK;Hills RK;Nielsen OJ;Freeman S;Ali A;Cahalin P;Hunter A;Thomas IF;Russell NH
通讯作者：
Russell NH
影响因子：
120.7
作者：
Koreth, John;Schlenk, Richard;Kopecky, Kenneth J.;Honda, Sumihisa;Sierra, Jorge;Djulbegovic, Benjamin J.;Wadleigh, Martha;DeAngelo, Daniel J.;Stone, Richard M.;Sakamaki, Hisashi;Appelbaum, Frederick R.;Doehner, Hartmut;Antin, Joseph H.;Soiffer, Robert J.;Cutler, Corey
通讯作者：
Cutler, Corey
影响因子：
11.4
作者：
Paiva, Bruno;Vidriales, Maria-Belen;Montesinos, Pau
通讯作者：
Montesinos, Pau